## Ganesh Mugundu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4184588/publications.pdf

Version: 2024-02-01

	1477746	1719596	
101	6	7	
citations	h-index	g-index	
7	7	1.40	
/	/	142	
docs citations	times ranked	citing authors	
	citations 7	101 6 citations h-index 7 7	

#	Article	IF	CITATIONS
1	Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model. Frontiers in Immunology, 2021, 12, 617316.	2.2	10
2	Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3834-3844.	3.2	36
3	Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 86, 97-108.	1.1	8
4	Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. Oncolmmunology, 2020, 9, 1748982.	2.1	23
5	Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology. Journal of Clinical Pharmacology, 2019, 59, 463-471.	1.0	11
6	Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 65-74.	0.8	7
7	Abstract CT022: A Phase Ib study of Wee1 inhibitor adavosertib in patients with advanced solid tumors. Cancer Research, 2019, 79, CT022-CT022.	0.4	6